Details

Autor(en) / Beteiligte

• Griffiths, Jessica
• Fox, Lisa
• Williamson, Paula R
• Adshead, Fiona
• Salman, Rustam Al-Shahi
• Anderson, Craig
• Bedson, Emma
• Bliss, Judith
• Boshoff, Ana
• Chen, Xiaoying
• Cranley, Denise
• Doran, Peter
• Gamble, Carrol
• Hood, Kerenza
• McGregor, Naomi
• McNamara, Carolyn
• Midha, Elis
• Moore, Keith
• Perkins, Alexis M
• Pett, Sarah
• Sydes, Matthew R

Titel

Quantifying the carbon footprint of clinical trials: guidance development and case studies

Ist Teil von

• BMJ open, 2024-01, Vol.14 (1), p.e075755-e075755

Ort / Verlag

England: British Medical Journal Publishing Group

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• BackgroundThe urgency of the climate crisis requires attention from biomedical research, not least clinical trials which can involve significant greenhouse gas emissions. The Low Carbon Clinical Trials Working Group set out a strategy to reduce the emissions of clinical trials, starting with the development of a method to measure their carbon footprint (CO2e).MethodsAs a first step, we developed a process map defining clinical trial core activities. Corresponding emission factors were sourced to convert activity data into greenhouse gas emissions. The subsequent method was applied to two Cancer Research UK (CRUK)-funded trials (the international randomised sarcoma trial CASPS (ISRCTN63733470) and the UK cohort-based breast cancer trial PRIMETIME (ISRCTN41579286)). A guidance document defining the scope, method and assumptions was written to allow application to any publicly funded/investigator initiated clinical trial.ResultsTrial specific activities over and above routine care were grouped into 10 modules covering trial set up, conduct and closure. We identified emission factors for all trial activities within both trials and used them to estimate their total carbon footprint. The carbon footprint of CASPS, an international phase 2 trial of an investigational medicinal product with 47 participants, was 72 tonnes CO2e, largely attributable to clinical trials unit emissions and staff travel. PRIMETIME, a UK-based phase 3 non-investigational medicinal product trial with 1962 patients, produced 89 tonnes CO2e, largely attributable to trial-specific in-person participant assessments.ConclusionWe have developed a method and guidance that trialists can use to determine the carbon footprint of clinical trials. The guidance can be used to identify carbon hotspots where alternative approaches to trial design and conduct could reduce a trial footprint, and where methodology research is required to investigate the potential impact of interventions taken to reduce carbon emissions. We will continue to refine the guidance to increase the potential application and improve usability.